Quick Takeaways
- BlackRock, Inc. filed SCHEDULE 13G for Apellis Pharmaceuticals Inc Common Stock (APLS).
- Disclosed ownership: 10%.
- Date of event: 31 Jan 2026.
BlackRock, Inc. - 31 Jan 2026 SCHEDULE 13G Report for Apellis Pharmaceuticals Inc Common Stock (APLS)
- Filing Manager
- BlackRock, Inc.
- Reporting Manager
- BlackRock, Inc.
- Symbol
- APLS
- Shares outstanding
- 125,981,648 shares
- Disclosed Ownership
- 13,228,073 shares
- Ownership
- 10%
- Form type
- SCHEDULE 13G
- Filing time
- 06 Feb 2026, 12:08:56 UTC
- Date of event
- 31 Jan 2026
- Previous filing
- 25 Apr 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"BlackRock, Inc. disclosed 10% ownership in Apellis Pharmaceuticals Inc Common Stock (APLS) on 31 Jan 2026."
What Changed
- Previous schedule filing date: 25 Apr 2025.
- Current filing was accepted on 06 Feb 2026, 12:08.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| BlackRock, Inc. | 10% | 13,228,073 | 13,026,072 | 0 | Spencer Fleming | Managing Director |